Project Grant K43TW012801
Award Date
9/1/24
Completion Date
8/31/29
Dollars Obligated
$109K
Federal Agency
Fogarty International Center
Federal Grant Program
93.989
Assistance Type
Project Grant
Place of Performance
Malawi
Similar Awards
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $479,204 to the University of Maryland, Baltimore to conduct research on severe malaria. The research aims to identify parasite variant surface antigens associated with severe malarial disease in Zambian children and adults. Key objectives include sequencing variant surface antigen transcripts from severe malaria cases...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $587,318 to Oregon Health & Science University (OHSU) to optimize the structural features of the antimalarial compound ELQ-596. The goal is to develop a next-generation ELQ compound for once-monthly oral prophylaxis against malaria in humans. The research aims to improve the drug's potency, metabolic stability,...
This $1,553,810 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will support a research project titled "Genomic Surveillance for Artemisinin Resistance in Africa: Moving Beyond a Candidate Gene Approach." The project aims to evaluate a genomic surveillance approach to identify mutations and altered biological functions in Plasmodium falciparum parasites that...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $467,400 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to the Regents of the University of California, San Francisco (UCSF) to develop precise field-friendly methods for quantification of antimalarial drugs in dried blood spot samples. The project aims to employ volumetric absorptive microsampling techniques and ultra-performance liquid chromatography-tandem mass spectrometry to quantify...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $1,373,790 to Oregon Health & Science University (OHSU) to optimize the structural features of the malaria drug candidate ELQ-596. The goal is to develop a next generation of ELQ compounds for once-monthly oral prophylaxis against malaria in humans. OHSU is collaborating with Drexel University and the Portland VA Research Foundation...
This $111,024 Project Grant awarded by the Fogarty International Center (CFDA 93.989 - International Research and Research Training) supports research to investigate the molecular and cellular mechanisms underlying placental malaria, a significant public health challenge in sub-Saharan Africa. The five-year grant, awarded to Mount Kenya University, a private non-profit research institution in Thika, Kenya, aims to: Identify the transcriptomic signatures of placental malaria-induced...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,303,086 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Maryland, Baltimore to conduct the "IMPACT OF EARLY CHILDHOOD MALARIA PREVENTION ON MALARIA RISK AT SCHOOL ENTRY (ERASE)" research project. The study aims to evaluate the long-term epidemiological impact of two malaria prevention interventions - seasonal malaria chemoprevention (SMC) and the...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $206,116 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Oregon Health & Science University (OHSU) to develop novel 4-aminoquinoline compounds as potential therapeutics against multi-drug resistant Plasmodium falciparum, the deadliest malaria parasite. The project aims to further develop a lead compound, MH02-060, which has demonstrated enhanced metabolic stability and in...
This $1,480,500 federal Project Grant award, titled "Epigenetic Drivers of Quiescence in Artemisinin-Resistant Plasmodium Falciparum Malaria", was provided by the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310). The grant, awarded to The Trustees of Columbia University in the City of New York, Health Sciences Division, aims to identify and functionally characterize the roles of non-coding RNAs (ncRNAs) in malaria parasite quiescence. The...
This Fogarty International Center (CFDA 93.989) Project Grant award of $559,341 to Henry Ford Health + Michigan State University Health Sciences will support a research study on tuberculosis (TB) in children under five years old in Malawi. The key objectives are to: Evaluate the accuracy of new non-invasive TB diagnostic strategies using stool and urine samples in hospitalized Malawian children under five with suspected pulmonary TB. Characterize the pharmacokinetics of first-line anti-TB...